Inclusion Criteria:

          -  Histologically confirmed BRAF V600 mutation-positive advanced solid malignancy that is
             metastatic or unresectable and for which standard curative or palliative measures do
             not exist or are no longer effective

          -  Normal or impaired hepatic function (hepatic function will be classified according to
             the NCI Organ Dysfunction Working Group criteria)

          -  For participants with hepatic impairment: Stable hepatic function for at least 2 weeks
             (greater than [>] 14 days) before Day 1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to
             (</=) 2

          -  Participants with a history of recent brain metastases must have completed any
             radiation therapy at least 4 weeks before Day 1, be without intervening signs of brain
             lesion progression and not require steroids before starting the protocol (Day 1).
             Participants with gliomas or known brain metastases who require anticonvulsants must
             be seizure free for 1 month prior to enrollment

          -  Life expectancy greater than or eual to (>/=) 8 weeks

          -  Adequate hematologic and renal function

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods that result in a failure rate
             of less than (<) 1 percent per year during the treatment period and for at least 6
             months after the last dose of study drug

        Exclusion Criteria:

          -  Allergy or hypersensitivity to components of the vemurafenib formulation

          -  Requirement for immediate or urgent treatment with twice a day vemurafenib and for
             whom the intermittent schedule of vemurafenib employed during Days 1-26 of this trial
             is not clinically acceptable

          -  Chemotherapy, biologic therapy, immunotherapy, or radiotherapy within 4 weeks prior to
             entering the study, or those who have not recovered from AEs because of agents
             administered more than 4 weeks earlier

          -  Gliomas or known brain metastases that require corticosteroids

          -  History of clinically significant cardiac or pulmonary dysfunction

          -  Human Immunodeficiency Virus (HIV)-positive participant requiring antiviral treatment
             including protease inhibitors

          -  Active infection or chronic infection requiring chronic suppressive antibiotics

          -  Pregnancy or breastfeeding at Day 1

          -  History of malabsorption or other clinically significant metabolic dysfunction

          -  Active autoimmune disease

          -  Current, recent (within 28 days prior to Day 1), or planned use of any investigational
             product outside this study